Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

CGTN: China’s economy shows vitality with innovative growth, booming market




BEIJING, Feb. 25, 2024 /PRNewswire/ — China’s provincial-level regions have set their economic growth targets for 2024, with figures ranging from 4.5 to 8 percent. Among them, over 20 regions are aiming to exceed 5 percent GDP growth.

Notably, these provinces share key priorities such as “new productive forces,” “boosting consumption” and “improving the business environment”.

The concept of “new productive forces” refers to a new form of productive forces, derived from continuous science and technology breakthroughs and innovation, that propel strategic emerging industries and future industries in an increasingly intelligent and information era.

Provinces have identified specific sectors to anchor new productive forces, including bio-manufacturing, the low-altitude economy, and emerging areas such as quantum technology and life sciences.

Efforts to integrate data with practical applications are also being made to bolster the digital economy. Zhejiang Province, for instance, is targeting a 9 percent increase in the added value of its core digital industries, and is seeking to ensure that 85 percent of major enterprises undergo digital transformation.

Likewise, several western inland provinces are looking to capitalize on their advantages in computing power to further industry digitization. For example, the Ningxia Hui Autonomous Region aims to intelligently upgrade traditional industries and empower small- and medium-sized enterprises digitally, aspiring for the digital economy to comprise over 36 percent of its regional GDP.

Additionally, fostering the development of the private sector has become a key focus. Several provinces plan to leverage financial policies to support private enterprises in major tech innovations, encourage their participation in key scientific projects, and direct private investment towards infrastructure.

This year, Jiangsu plans to roll out specialized policies to stimulate private investment, while Guangxi is set to guide financial institutions to enhance support for first-time credit loans to private businesses. Also, Hainan will create a fund pool to assist companies with good credit but temporary financial difficulties.

Meanwhile, provinces and municipalities like Jiangxi, Liaoning, Chongqing and Shanxi are improving their regulatory frameworks to protect investment rights. They aim to eliminate indirect barriers to market entry, ensuring a level playing field for businesses of all types.

Drawn by the improving and welcoming business environment, along with the vast consumer market, foreign-funded enterprises are confident in their long-term investment prospects in China.

Major multinational corporations from various sectors, including KFC and Standard Chartered, have recently boosted their investments in China. The country continues to be a prime investment destination due to offering promising innovation opportunities, comprehensive industrial support and creating a conducive business environment.

In 2023, German direct investment in China increased by 4.3 percent, reaching a record high of 11.9 billion euros ($12.7 billion), according to official Bundesbank data analyzed by the IW institute. Additionally, China’s share of Germany’s total overseas investments climbed to 10.3 percent last year, marking the highest level since 2014.

Booming consumer market

Since 2023, China’s consumer market has shown a robust recovery. Last year, total retail sales of consumer goods reached 47.15 trillion yuan (about 6.63 trillion U.S. dollars), up 7.2 percent from the previous year, according to the National Bureau of Statistics. Online retail sales saw an 11 percent increase, with physical goods’ online sales constituting 27.6 percent of the total retail sales.

The rise of new consumer models, such as e-commerce, has expanded the range of sales channels available in the consumer market, offering users a more varied experience, observed Pan Helin, a researcher at Zhejiang University.

The revitalization of the consumer market has also been reflected in the travel sector. During this year’s Spring Festival holiday, there was a high level of enthusiasm for travel. Data shows that the number of visitors to major cultural and tourism sites nationwide reached 123 million, marking a 22.8 percent increase compared with the same period in 2023.

The increased travel and cultural activities during the Spring Festival also fueled an uptick in entertainment spending, especially in the film industry. As of 1:15 p.m. Friday, box office revenue in China from the Spring Festival holiday (including pre-sale) has surpassed 7 billion yuan (approximately $983.3 million), according to Dengta Pro, the data analysis arm of China’s leading film-ticketing platform Taopiaopiao.

Pan noted that the increasing consumer demand for a higher quality of life and richer experiences signifies a shift in consumption patterns. This trend, coupled with a growing enthusiasm for shopping and leisure activities, indicates a steady recovery in China’s consumer market. 

View original content:

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024




STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision,c3956826

The following files are available for download:

Invitation to presentation of EQT AB’s Q1 Announcement 2024,c3285895

EQT AB Group


View original content:

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs



  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo –

Cision View original content to download multimedia:

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update




VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn.


Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo –

Cision View original content:

Continue Reading